# Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

> **NCT06923956** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 14 (actual)

## Conditions studied

- Hypercholesterolaemia
- Mixed Dyslipidaemia
- Cardiovascular Diseases

## Interventions

- **DRUG:** Bempedoic Acid Film Coated Tablet
- **DRUG:** Nilemdo® (Bempedoic Acid) Film-coated tablets

## Key facts

- **NCT ID:** NCT06923956
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-04
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-02-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06923956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06923956, "Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting Conditions.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06923956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*